Trump reportedly plans to remove FDA chief Marty Makary

Reports indicate that former President Donald Trump intends to remove Marty Makary from his position as Commissioner of the Food and Drug Administration (FDA). This potential move, if finalized, would mark another significant shift in the agency's leadership under a potential Trump administration. Sources close to the matter have shared this information with major news outlets, though they stress that the decision remains fluid.

Makary, a surgical oncologist, was appointed to lead the FDA in March of last year. His tenure has been characterized by a focus on healthcare costs and the perceived failures of modern medicine, as outlined in his various books. He was also a notable supporter of Robert F. Kennedy Jr.'s "Make America Healthy Again" movement, aligning himself with a platform critical of established health institutions.

The reported intention to dismiss Makary comes amid ongoing scrutiny of the FDA's decisions and procedures, particularly concerning the abortion pill mifepristone. This issue has been a focal point of debate and criticism, and it appears to be a significant factor in the discussions surrounding Makary's leadership. The departure of thousands of employees, either through layoffs or voluntary resignations, during the tenure of both Makary and Health Secretary Robert F. Kennedy Jr. also raises questions about the internal dynamics of the agency.

As a Slovak publication, we observe these developments with interest, noting the potential impact on regulatory bodies and public health policy in the United States. The frequent changes in leadership and the controversies surrounding key decisions highlight the volatile nature of political appointments and their influence on critical government functions. The focus on issues like mifepristone underscores the deeply divided landscape of reproductive rights in the U.S., a topic that continues to generate significant political and social debate.